A Phase 1 interventional study of MK-1167 and Donepezil in Alzheimer's Disease, sponsored by Merck Sharp & Dohme LLC. Completed at 3 sites in United States. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-10-14.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Alzheimer Disease by Merck & Co., Inc — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · Merck & Co., Inc.
Among the 31 studies in Alzheimer Disease by Merck & Co., Inc, this one is the 18th largest by enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2024, is one of 18 in phase 1, and was the 28th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.
Browse Alzheimer Disease studies →1 of the 31 studies in Alzheimer Disease by Merck & Co., Inc is open now, in 11 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 8 more countries
Ages 50–85
By country, each count listing its studies:
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 9 · Phase 3 4
First in 2003; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 70 across 3,021 interventional studies indexed under Alzheimer Disease.
Median enrollment 34 across the 29 interventional studies, 11 across the 1 observational. Of the 29 that completed or were terminated, 20 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 31 studies in Alzheimer Disease by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to assess the safety and efficacy of MK-1167 administered to participants with Alzheimer's Disease (AD) receiving stable Donepezil treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive 6mg MK-1167 oral loading doses once daily (QD) Days 1 to 7, followed by 3mg MK-1167 oral maintenance doses QD Days 8 to 21. Participants also receive 10mg oral Donepezil on Days -3 to 21.
Drug: MK-1167 · Drug: Donepezil
Participants receive dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also receive 10mg oral Donepezil QD on Days -3 to 21.
Drug: Donepezil · Drug: Placebo
Participants receive 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31.
Drug: MK-1167 · Drug: Donepezil
Participants receive dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also receive 10mg oral Donepezil QD on Days -3 to 31.
Drug: Donepezil · Drug: Placebo
Number of Participants Who Experienced an Adverse Event (AE)
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE were reported.
Time frame: Up to approximately 7 weeks
Number of Participants Who Discontinued Study Treatment Due to an AE
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE were reported.
Time frame: Up to approximately 4 weeks
Panel A: Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC0-24) After Administration of 6mg of MK-1167
AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Blood samples were collected at pre-specified intervals for the determination of AUC0-24. Per protocol, AUC0-24 was based on noncompartmental analysis, and a geometric mean AUC0-24 value was presented for Panel A participants after administration of 6mg of MK-1167.
Time frame: Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Panel A: AUC0-24 After Administration of 3mg of MK-1167
AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Blood samples were collected at pre-specified intervals for the determination of AUC0-24. Per protocol, AUC0-24 was based on noncompartmental analysis, and a geometric mean AUC 0-24 value was presented for Panel A participants after administration of 3mg of MK-1167.
Time frame: Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Panel B: AUC0-24 After Administration of 6mg of MK-1167
AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Blood samples were collected at pre-specified intervals for the determination of AUC0-24. Per protocol, AUC0-24 was based on noncompartmental analysis, and a geometric mean AUC0-24 value was presented for Panel B participants after administration of 6mg of MK-1167.
Time frame: Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Panel A: Maximum Plasma Concentration (Cmax) After Administration of 6mg of MK-1167
Cmax was defined as the maximum serum concentration of MK-1167 reached. Blood samples were collected at pre-specified timepoints for the determination of Cmax. Per protocol, Cmax was based on noncompartmental analysis, and a geometric mean Cmax value was presented for Panel A participants after administration of 6mg of MK-1167.
Time frame: Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Panel A: Cmax After Administration of 3mg of MK-1167
Cmax was defined as the maximum serum concentration of MK-1167 reached. Blood samples were collected at pre-specified timepoints for the determination of Cmax. Per protocol, Cmax was based on noncompartmental analysis, and a geometric mean Cmax value was presented for Panel A participants after administration of 3mg of MK-1167.
Time frame: Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Panel B: Cmax After Administration of 6mg of MK-1167
Cmax was defined as the maximum serum concentration of MK-1167 reached. Blood samples were collected at pre-specified timepoints for the determination of Cmax. Per protocol, Cmax was based on noncompartmental analysis, and a geometric mean Cmax value was presented for Panel B participants after administration of 6mg of MK-1167.
Time frame: Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Panel A: Plasma Concentration at 24 Hours (C24) After Administration of 6mg of MK-1167
C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Per protocol, C24 was based on noncompartmental analysis, and a geometric mean C24 value was presented for Panel A participants after administration of 6mg of MK-1167.
Time frame: Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Panel A: C24 After Administration of 3mg of MK-1167
C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Per protocol, C24 was based on noncompartmental analysis, and a geometric mean C24 value was presented for Panel A participants after administration of 3mg of MK-1167.
Time frame: Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Panel B: C24 After Administration of 6mg of MK-1167
C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Per protocol, C24 was based on noncompartmental analysis, and a geometric mean C24 value was presented for Panel B participants after administration of 6mg of MK-1167.
Time frame: Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Panel A: Time to Maximum Plasma Concentration (Tmax) After Administration of 6mg of MK-1167
Tmax was defined as time to the maximum concentration of MK-1167 reached. Blood samples were collected at pre-specified intervals for the determination of Tmax. Per protocol, Tmax was based on noncompartmental analysis, and a median Tmax value was presented for Panel A participants after administration of 6mg of MK-1167.
Time frame: Day 1: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Panel A: Tmax After Administration of 3mg of MK-1167
Tmax was defined as time to the maximum concentration of MK-1167 reached. Blood samples were collected at pre-specified intervals for the determination of Tmax. Per protocol, Tmax was based on noncompartmental analysis, and a median Tmax value was presented for Panel A participants after administration of 3mg of MK-1167.
Time frame: Days 8, 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Panel B: Tmax After Administration of 6mg of MK-1167
Tmax was defined as time to the maximum concentration of MK-1167 reached. Blood samples were collected at pre-specified intervals for the determination of Tmax. Per protocol, Tmax was based on noncompartmental analysis, and a median Tmax value was presented for Panel B participants after administration of 6mg of MK-1167.
Time frame: Days 1, 23, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Panel A: Apparent Clearance (CL/F) After Administration of 3mg of MK-1167
CL/F is the rate at which the MK-1167 is completely removed from plasma. Blood samples were collected at pre-specified intervals for the determination of CL/F. Per protocol, CL/F was based on noncompartmental analysis, and a geometric mean CL/F value was presented for Panel A participants after administration of 3mg of MK-1167.
Time frame: Day 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose
Panel B: CL/F After Administration of 6mg of MK-1167
CL/F is the rate at which the MK-1167 is completely removed from plasma. Blood samples were collected at pre-specified intervals for the determination of CL/F. Per protocol, CL/F was based on noncompartmental analysis, and a geometric mean CL/F value was presented for Panel B participants after administration of 6mg of MK-1167.
Time frame: Day 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose
Panel A: Apparent Terminal Half-Life (t1/2) After Administration of 3mg of MK-1167
t1/2 is defined as the time required to divide plasma concentration of MK-1167 by half after reaching pseudo-equilibrium. Blood samples were collected at pre-specified intervals for the determination of t1/2. Per protocol, t1/2 was based on noncompartmental analysis, and a geometric mean t1/2 value was presented for Panel A participants after administration of 3mg of MK-1167.
Time frame: Day 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose
Panel B: t1/2 After Administration of 6mg of MK-1167
t1/2 was defined as the time required to divide plasma concentration of MK-1167 by half after reaching pseudo-equilibrium. Blood samples were collected at pre-specified timepoints for the determination of t1/2. Per protocol, t1/2 was based on noncompartmental analysis, and a geometric mean t1/2 value was presented for Panel B participants after administration of 6mg of MK-1167.
Time frame: Day 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose
Panel A: Apparent Volume of Distribution (Vz/F) After Administration of 3mg of MK-1167
Vz/F was the apparent volume of distribution of MK-1167. Blood samples were collected at pre-specified intervals for the determination of Vz/F. Per protocol, Vz/F was based on noncompartmental analysis, and a geometric mean Vz/F value was presented for Panel A participants after administration of 3mg of MK-1167.
Time frame: Day 21: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose
Panel B: Vz/F After Administration of 6mg of MK-1167
Vz/F was the apparent volume of distribution of MK-1167. Blood samples were collected at pre-specified intervals for the determination of Vz/F. Per protocol, Vz/F was based on noncompartmental analysis, and a geometric mean Vz/F value was presented for Panel B participants after administration of 6mg of MK-1167.
Time frame: Day 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 120, 240, 360 and 480 hours postdose
Panel B: Day 23 to Day 1 Accumulation Ratio of AUC0-24 After Administration of 6mg of MK-1167
Blood samples were collected at pre-specified timepoints to determine AUC0-24 on Days 1 and 23. AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Accumulation ratio of MK-1167 Day 23 to Day 1 was calculated as Day 23 AUC0-24/Day 1 AUC0-24.
Time frame: Days 1, 23: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Panel B: Day 31 to Day 1 Accumulation Ratio of AUC0-24 After Administration of 6mg of MK-1167
Blood samples were collected at pre-specified timepoints to determine AUC0-24 on Days 1 and 31. AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Accumulation ratio of MK-1167 Day 31 to Day 1 was calculated as Day 31 AUC0-24/Day 1 AUC0-24.
Time frame: Days 1, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Panel B: Day 23 to Day 1 Accumulation Ratio of Cmax After Administration of 6mg of MK-1167
Blood samples were collected at pre-specified timepoints to determine Cmax on Days 1 and 23. Cmax was defined as the maximum serum concentration of MK-1167 reached. Accumulation ratio of MK-1167 Day 23 to Day 1 was calculated as Day 23 Cmax/Day 1 Cmax.
Time frame: Days 1, 23: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Panel B: Day 31 to Day 1 Accumulation Ratio of Cmax After Administration of 6mg of MK-1167
Blood samples were collected at pre-specified timepoints to determine Cmax on Days 1 and 31. Cmax was defined as the maximum serum concentration of MK-1167 reached. Accumulation ratio of MK-1167 Day 31 to Day 1 was calculated as Day 31 Cmax/Day 1 Cmax.
Time frame: Days 1, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Panel B: Day 23 to Day 1 Accumulation Ratio of C24 After Administration of 6mg of MK-1167
Blood samples were collected at pre-specified timepoints to determine C24 on Days 1 and 23. C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Accumulation ratio of MK-1167 Day 23 to Day 1 was calculated as Day 23 C24/Day 1 C24.
Time frame: Days 1, 23: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
Panel B: Day 31 to Day 1 Accumulation Ratio of C24 After Administration of 6mg of MK-1167
Blood samples were collected at pre-specified timepoints to determine C24 on Days 1 and 31. C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Accumulation ratio of MK-1167 Day 31 to Day 1 was calculated as Day 31 C24/Day 1 C24.
Time frame: Days 1, 31: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose
| Milestone | Panel A: MK-1167 + Donepezil 10mg QD | Panel A: Placebo to MK-1167 + Donepezil 10mg QD | Panel B: MK-1167 6mg QD + Donepezil 10mg QD | Panel B: Placebo to MK-1167 + Donepezil 10mg QD |
|---|---|---|---|---|
| Started | 12 | 4 | 9 | 3 |
| Treated | 12 | 4 | 9 | 3 |
| Panel a participants who received 6mg of mk-1167 | 12 | 0 | 0 | 0 |
| Panel a participants who received 3mg of mk-1167 | 12 | 0 | 0 | 0 |
| Completed | 10 | 4 | 8 | 3 |
| Not completed | 2 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 | 0 |
| Withdrew: Serious adverse event | 0 | 0 | 1 | 0 |
AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Blood samples were collected at pre-specified intervals for the determination of AUC0-24. Per protocol, AUC0-24 was based on noncompartmental analysis, and a geometric mean AUC0-24 value was presented for Panel A participants after administration of 6mg of MK-1167.
| μM*hour | Panel A: MK-1167 6mg QD + Donepezil 10mg QD |
|---|---|
| Panel A: Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC0-24) After Administration of 6mg of MK-1167 | 2.17 (1.22 to 3.84) |
AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Blood samples were collected at pre-specified intervals for the determination of AUC0-24. Per protocol, AUC0-24 was based on noncompartmental analysis, and a geometric mean AUC 0-24 value was presented for Panel A participants after administration of 3mg of MK-1167.
| μM*hour | Panel A: MK-1167 3mg QD + Donepezil 10mg QD |
|---|---|
| Day 8 | 8.70 (4.95 to 15.3) |
| Day 21 | 8.08 (4.56 to 14.3) |
AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Blood samples were collected at pre-specified intervals for the determination of AUC0-24. Per protocol, AUC0-24 was based on noncompartmental analysis, and a geometric mean AUC0-24 value was presented for Panel B participants after administration of 6mg of MK-1167.
| μM*hour | Panel B: MK-1167 6mg QD + Donepezil 10mg QD |
|---|---|
| Day 1 | 2.48 (2.04 to 3.01) |
| Day 23 | 22.2 (18.1 to 27.1) |
| Day 31 | 22.9 (18.8 to 28.0) |
Cmax was defined as the maximum serum concentration of MK-1167 reached. Blood samples were collected at pre-specified timepoints for the determination of Cmax. Per protocol, Cmax was based on noncompartmental analysis, and a geometric mean Cmax value was presented for Panel A participants after administration of 6mg of MK-1167.
| μmol/Liter | Panel A: MK-1167 6mg QD + Donepezil 10mg QD |
|---|---|
| Panel A: Maximum Plasma Concentration (Cmax) After Administration of 6mg of MK-1167 | 0.129 (0.0731 to 0.228) |
Cmax was defined as the maximum serum concentration of MK-1167 reached. Blood samples were collected at pre-specified timepoints for the determination of Cmax. Per protocol, Cmax was based on noncompartmental analysis, and a geometric mean Cmax value was presented for Panel A participants after administration of 3mg of MK-1167.
| μmol/Liter | Panel A: MK-1167 3mg QD + Donepezil 10mg QD |
|---|---|
| Day 8 | 0.434 (0.247 to 0.761) |
| Day 21 | 0.413 (0.234 to 0.729) |
Cmax was defined as the maximum serum concentration of MK-1167 reached. Blood samples were collected at pre-specified timepoints for the determination of Cmax. Per protocol, Cmax was based on noncompartmental analysis, and a geometric mean Cmax value was presented for Panel B participants after administration of 6mg of MK-1167.
| μmol/Liter | Panel B: MK-1167 6mg QD + Donepezil 10mg QD |
|---|---|
| Day 1 | 0.145 (0.121 to 0.174) |
| Day 23 | 1.11 (0.919 to 1.35) |
| Day 31 | 1.14 (0.941 to 1.38) |
C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Per protocol, C24 was based on noncompartmental analysis, and a geometric mean C24 value was presented for Panel A participants after administration of 6mg of MK-1167.
| μmol/Liter | Panel A: MK-1167 6mg QD + Donepezil 10mg QD |
|---|---|
| Panel A: Plasma Concentration at 24 Hours (C24) After Administration of 6mg of MK-1167 | 0.0902 (0.0500 to 0.163) |
C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Per protocol, C24 was based on noncompartmental analysis, and a geometric mean C24 value was presented for Panel A participants after administration of 3mg of MK-1167.
| μmol/Liter | Panel A: MK-1167 3mg QD + Donepezil 10mg QD |
|---|---|
| Day 8 | 0.362 (0.203 to 0.647) |
| Day 21 | 0.313 (0.174 to 0.565) |
C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Per protocol, C24 was based on noncompartmental analysis, and a geometric mean C24 value was presented for Panel B participants after administration of 6mg of MK-1167.
| μmol/Liter | Panel B: MK-1167 6mg QD + Donepezil 10mg QD |
|---|---|
| Day 1 | 0.0917 (0.0731 to 0.115) |
| Day 23 | 0.729 (0.576 to 0.922) |
| Day 31 | 0.875 (0.691 to 1.11) |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE were reported.
| Participants | Panel A: MK-1167 6mg QD + Donepezil 10mg QD | Panel A: MK-1167 3mg QD + Donepezil 10mg QD | Panel A: Placebo to MK-1167 + Donepezil 10mg QD | Panel B: MK-1167 6mg QD+ Donepezil 10mg QD | Panel B: Placebo to MK-1167 + Donepezil 10mg QD |
|---|---|---|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 3 | 5 | 2 | 6 | 0 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE were reported.
| Participants | Panel A: MK-1167 6mg QD + Donepezil 10mg QD | Panel A: MK-1167 3mg QD + Donepezil 10mg QD | Panel A: Placebo to MK-1167 + Donepezil 10mg QD | Panel B: MK-1167 6mg QD + Donepezil 10mg QD | Panel B: Placebo to MK-1167 + Donepezil 10mg QD |
|---|---|---|---|---|---|
| Number of Participants Who Discontinued Study Treatment Due to an AE | 0 | 0 | 0 | 1 | 0 |
Tmax was defined as time to the maximum concentration of MK-1167 reached. Blood samples were collected at pre-specified intervals for the determination of Tmax. Per protocol, Tmax was based on noncompartmental analysis, and a median Tmax value was presented for Panel A participants after administration of 6mg of MK-1167.
| hours | Panel A: MK-1167 6mg QD + Donepezil 10mg QD |
|---|---|
| Panel A: Time to Maximum Plasma Concentration (Tmax) After Administration of 6mg of MK-1167 | 1.54 (0.50 to 8.00) |
Tmax was defined as time to the maximum concentration of MK-1167 reached. Blood samples were collected at pre-specified intervals for the determination of Tmax. Per protocol, Tmax was based on noncompartmental analysis, and a median Tmax value was presented for Panel A participants after administration of 3mg of MK-1167.
| hours | Panel A: MK-1167 3mg QD + Donepezil 10mg QD |
|---|---|
| Day 8 | 6.00 (0.00 to 23.97) |
| Day 21 | 4.01 (1.22 to 11.92) |
Tmax was defined as time to the maximum concentration of MK-1167 reached. Blood samples were collected at pre-specified intervals for the determination of Tmax. Per protocol, Tmax was based on noncompartmental analysis, and a median Tmax value was presented for Panel B participants after administration of 6mg of MK-1167.
| hours | Panel B: MK-1167 6mg QD + Donepezil 10mg QD |
|---|---|
| Day 1 | 1.08 (0.48 to 5.78) |
| Day 23 | 4.03 (0.58 to 11.92) |
| Day 31 | 2.97 (0.42 to 11.90) |
CL/F is the rate at which the MK-1167 is completely removed from plasma. Blood samples were collected at pre-specified intervals for the determination of CL/F. Per protocol, CL/F was based on noncompartmental analysis, and a geometric mean CL/F value was presented for Panel A participants after administration of 3mg of MK-1167.
| Liter/hour | Panel A: MK-1167 3mg QD + Donepezil 10mg QD |
|---|---|
| Panel A: Apparent Clearance (CL/F) After Administration of 3mg of MK-1167 | 0.879 ± 166.9 |
CL/F is the rate at which the MK-1167 is completely removed from plasma. Blood samples were collected at pre-specified intervals for the determination of CL/F. Per protocol, CL/F was based on noncompartmental analysis, and a geometric mean CL/F value was presented for Panel B participants after administration of 6mg of MK-1167.
| Liter/hour | Panel B: MK-1167 6mg QD + Donepezil 10mg QD |
|---|---|
| Panel B: CL/F After Administration of 6mg of MK-1167 | 0.606 ± 32.3 |
t1/2 is defined as the time required to divide plasma concentration of MK-1167 by half after reaching pseudo-equilibrium. Blood samples were collected at pre-specified intervals for the determination of t1/2. Per protocol, t1/2 was based on noncompartmental analysis, and a geometric mean t1/2 value was presented for Panel A participants after administration of 3mg of MK-1167.
| hours | Panel A: MK-1167 3 mg QD + Donepezil 10mg QD |
|---|---|
| Panel A: Apparent Terminal Half-Life (t1/2) After Administration of 3mg of MK-1167 | 194 ± 48.2 |
t1/2 was defined as the time required to divide plasma concentration of MK-1167 by half after reaching pseudo-equilibrium. Blood samples were collected at pre-specified timepoints for the determination of t1/2. Per protocol, t1/2 was based on noncompartmental analysis, and a geometric mean t1/2 value was presented for Panel B participants after administration of 6mg of MK-1167.
| hour | Panel B: MK-1167 6mg QD + Donepezil 10mg QD |
|---|---|
| Panel B: t1/2 After Administration of 6mg of MK-1167 | 193 ± 40.4 |
Vz/F was the apparent volume of distribution of MK-1167. Blood samples were collected at pre-specified intervals for the determination of Vz/F. Per protocol, Vz/F was based on noncompartmental analysis, and a geometric mean Vz/F value was presented for Panel A participants after administration of 3mg of MK-1167.
| Liter | Panel A: MK-1167 3mg QD + Donepezil 10mg QD |
|---|---|
| Panel A: Apparent Volume of Distribution (Vz/F) After Administration of 3mg of MK-1167 | 246 ± 166.6 |
Vz/F was the apparent volume of distribution of MK-1167. Blood samples were collected at pre-specified intervals for the determination of Vz/F. Per protocol, Vz/F was based on noncompartmental analysis, and a geometric mean Vz/F value was presented for Panel B participants after administration of 6mg of MK-1167.
| Liter | Panel B: MK-1167 6mg QD + Donepezil 10mg QD |
|---|---|
| Panel B: Vz/F After Administration of 6mg of MK-1167 | 169 ± 19.7 |
Blood samples were collected at pre-specified timepoints to determine AUC0-24 on Days 1 and 23. AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Accumulation ratio of MK-1167 Day 23 to Day 1 was calculated as Day 23 AUC0-24/Day 1 AUC0-24.
| Ratio | Panel B: MK-1167 6mg QD + Donepezil 10mg QD |
|---|---|
| Panel B: Day 23 to Day 1 Accumulation Ratio of AUC0-24 After Administration of 6mg of MK-1167 | 8.95 (7.80 to 10.27) |
Blood samples were collected at pre-specified timepoints to determine AUC0-24 on Days 1 and 31. AUC0-24 was defined as the area under the concentration-time curve of MK-1167 from time zero to 24 hours. Accumulation ratio of MK-1167 Day 31 to Day 1 was calculated as Day 31 AUC0-24/Day 1 AUC0-24.
| Ratio | Panel B: MK-1167 6mg QD + Donepezil 10mg QD |
|---|---|
| Panel B: Day 31 to Day 1 Accumulation Ratio of AUC0-24 After Administration of 6mg of MK-1167 | 9.26 (8.08 to 10.62) |
Blood samples were collected at pre-specified timepoints to determine Cmax on Days 1 and 23. Cmax was defined as the maximum serum concentration of MK-1167 reached. Accumulation ratio of MK-1167 Day 23 to Day 1 was calculated as Day 23 Cmax/Day 1 Cmax.
| Ratio | Panel B: MK-1167 6mg QD + Donepezil 10mg QD |
|---|---|
| Panel B: Day 23 to Day 1 Accumulation Ratio of Cmax After Administration of 6mg of MK-1167 | 7.69 (6.46 to 9.16) |
Blood samples were collected at pre-specified timepoints to determine Cmax on Days 1 and 31. Cmax was defined as the maximum serum concentration of MK-1167 reached. Accumulation ratio of MK-1167 Day 31 to Day 1 was calculated as Day 31 Cmax/Day 1 Cmax.
| Ratio | Panel B: MK-1167 6mg QD + Donepezil 10mg QD |
|---|---|
| Panel B: Day 31 to Day 1 Accumulation Ratio of Cmax After Administration of 6mg of MK-1167 | 7.88 (6.62 to 9.38) |
Blood samples were collected at pre-specified timepoints to determine C24 on Days 1 and 23. C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Accumulation ratio of MK-1167 Day 23 to Day 1 was calculated as Day 23 C24/Day 1 C24.
| Ratio | Panel B: MK-1167 6mg QD + Donepezil 10mg QD |
|---|---|
| Panel B: Day 23 to Day 1 Accumulation Ratio of C24 After Administration of 6mg of MK-1167 | 7.94 (6.64 to 9.50) |
Blood samples were collected at pre-specified timepoints to determine C24 on Days 1 and 31. C24 was defined as the serum concentration of MK-1167 reached at 24 hours. Blood samples were collected at pre-specified timepoints for the determination of C24. Accumulation ratio of MK-1167 Day 31 to Day 1 was calculated as Day 31 C24/Day 1 C24.
| Ratio | Panel B: MK-1167 6mg QD + Donepezil 10mg QD |
|---|---|
| Panel B: Day 31 to Day 1 Accumulation Ratio of C24 After Administration of 6mg of MK-1167 | 9.54 (7.97 to 11.40) |
Collected over Up to approximately 25 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panel A: MK-1167 6mg QD + Donepezil 10mg QD | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| Panel A: MK-1167 3mg QD + Donepezil 10mg QD | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| Panel A: Placebo to MK-1167 + Donepezil 10mg QD | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Panel B: MK-1167 6mg QD + Donepezil 10mg QD | 0/9 (0%) | 1/9 (11.1%) | 6/9 (66.7%) |
| Panel B: Placebo to MK-1167 + Donepezil 10mg QD | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Event | Panel A: MK-1167 6mg QD + Donepezil 10mg QD | Panel A: MK-1167 3mg QD + Donepezil 10mg QD | Panel A: Placebo to MK-1167 + Donepezil 10mg QD | Panel B: MK-1167 6mg QD + Donepezil 10mg QD | Panel B: Placebo to MK-1167 + Donepezil 10mg QD |
|---|---|---|---|---|---|
| Deep vein thrombosisVascular disorders | 0/12 | 0/12 | 0/4 | 1/9 | 0/3 |
| Event | Panel A: MK-1167 6mg QD + Donepezil 10mg QD | Panel A: MK-1167 3mg QD + Donepezil 10mg QD | Panel A: Placebo to MK-1167 + Donepezil 10mg QD | Panel B: MK-1167 6mg QD + Donepezil 10mg QD | Panel B: Placebo to MK-1167 + Donepezil 10mg QD |
|---|---|---|---|---|---|
| DizzinessNervous system disorders | 0/12 | 0/12 | 1/4 | 1/9 | 0/3 |
| IrritabilityPsychiatric disorders | 0/12 | 0/12 | 1/4 | 0/9 | 0/3 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/12 | 0/12 | 1/4 | 0/9 | 0/3 |
| Orthostatic hypotensionVascular disorders | 0/12 | 0/12 | 1/4 | 0/9 | 0/3 |
| PallorVascular disorders | 0/12 | 0/12 | 1/4 | 0/9 | 0/3 |
| Upper respiratory tract infectionInfections and infestations | 0/12 | 0/12 | 0/4 | 2/9 | 0/3 |
| DiarrhoeaGastrointestinal disorders | 2/12 | 0/12 | 0/4 | 0/9 | 0/3 |
| Ear painEar and labyrinth disorders | 0/12 | 0/12 | 0/4 | 1/9 | 0/3 |
| ConstipationGastrointestinal disorders | 0/12 | 0/12 | 0/4 | 1/9 | 0/3 |
| NauseaGastrointestinal disorders | 0/12 | 0/12 | 0/4 | 1/9 | 0/3 |
All randomized participants
| Age, Continuous(Years) | Panel A: MK-1167 + Donepezil 10mg QD | Panel A: Placebo to MK-1167 + Donepezil 10mg QD | Panel B: MK-1167 6mg QD + Donepezil 10mg QD | Panel B: Placebo to MK-1167 + Donepezil 10mg QD | Total |
|---|---|---|---|---|---|
| Mean | 68.2 ± 8.2 | 63.5 ± 8.7 | 69.9 ± 8.6 | 75.3 ± 2.9 | 68.8 ± 8.2 |
| Sex: Female, Male(Participants) | Panel A: MK-1167 + Donepezil 10mg QD | Panel A: Placebo to MK-1167 + Donepezil 10mg QD | Panel B: MK-1167 6mg QD + Donepezil 10mg QD | Panel B: Placebo to MK-1167 + Donepezil 10mg QD | Total |
|---|---|---|---|---|---|
| Female | 6 | 3 | 3 | 1 | 13 |
| Male | 6 | 1 | 6 | 2 | 15 |
| Ethnicity (NIH/OMB)(Participants) | Panel A: MK-1167 + Donepezil 10mg QD | Panel A: Placebo to MK-1167 + Donepezil 10mg QD | Panel B: MK-1167 6mg QD + Donepezil 10mg QD | Panel B: Placebo to MK-1167 + Donepezil 10mg QD | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 2 | 4 | 2 | 12 |
| Not Hispanic or Latino | 8 | 2 | 5 | 1 | 16 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Panel A: MK-1167 + Donepezil 10mg QD | Panel A: Placebo to MK-1167 + Donepezil 10mg QD | Panel B: MK-1167 6mg QD + Donepezil 10mg QD | Panel B: Placebo to MK-1167 + Donepezil 10mg QD | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 2 | 3 | 0 | 11 |
| White | 6 | 2 | 6 | 3 | 17 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Mar 2024 to primary completion in Sep 2024, 5 months.
Results were first posted in Oct 2025, 1 year after primary completion.
Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 5 months is below that.
Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-1167